Yokogawa establishes innovation center in Allschwil
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.
Yokogawa Innovation Switzerland GmbH is to start business operations in August, as detailed by a press release issued by Yokogawa Electric Corporation. The establishment of the new Swiss subsidiary in Allschwil has come about thanks to the support offered by Basel Area Business & Innovation, the investment and innovation promotion agency. This organization is responsible for operating the Switzerland Innovation Park Basel Area, where Yokogawa is using office and lab space. Yokogawa also opted for Allschwill due to its proximity to Basel, the “European center of the biotechnology and life science industry”, which it describes as an “ideal location”.
In Allschwil, Yokogawa will seek to drive forward innovations in the field of biotechnology. The market for bio-based products is set to continually expand, and for this reason Yokogawa is keen to exploit the expertise and personnel resources on offer in the Basel region in order to “explore new business opportunities, and forge alliances with other entities that have world-leading technologies”, the press release states. In addition, existing activities in the field of industrial automation based in Switzerland will now also be integrated within the new location.
In terms of the future research and development activities in Allschwil, Yokogawa is planning to benefit from Switzerland’s highly competitive position and skilled workforce. Both of these aspects should ensure that Yokogawa is in a position to comply with the Sustainable Development Goals (SDGs) of the United Nations and contribute to the circular economy.
Share this article
You may also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More